4.4 Review

GPCRs: The most promiscuous druggable receptor of the mankind

期刊

SAUDI PHARMACEUTICAL JOURNAL
卷 29, 期 6, 页码 539-551

出版社

ELSEVIER
DOI: 10.1016/j.jsps.2021.04.015

关键词

Arrestin; Drugs; G proteins; GPCR; GRKs; Heterodimerization; Signaling

向作者/读者索取更多资源

All physiological events in living organisms originate as specific chemical/biochemical signals on the cell surface and are translated to maintain optimum performance and homeostasis. GPCRs, constituting roughly 800 genes in humans, control various pathophysiological disorders, with around 40% of drugs targeting mainly GPCRs in the market. Only approximately one-third of GPCR families have been characterized, indicating the complexity of these crucial signaling molecules in biological systems.
All physiological events in living organisms originated as specific chemical/biochemical signals on the cell surface and transmitted into the cytoplasm. This signal is translated within milliseconds-hours to a specific and unique order required to maintain optimum performance and homeostasis of living organisms. Examples of daily biological functions include neuronal communication and neurotransmission in the process of learning and memory, secretion (hormones, sweat, and saliva), muscle contraction, cellular growth, differentiation and migration during wound healing, and immunity to fight infections. Among the different transducers for such life-dependent signals is the large family of G protein-coupled receptors (GPCRs). GPCRs constitute roughly 800 genes, corresponding to 2% of the human genome. While GPCRs control a plethora of pathophysiological disorders, only approximately one-third of GPCR families have been deorphanized and characterized. Recent drug data show that around 40% of the recommended drugs available in the market target mainly GPCRs. In this review, we presented how such system signals, either through G protein or via other players, independent of G protein, function within the biological system. We also discussed drugs in the market or clinical trials targeting mainly GPCRs in various diseases, including cancer. (c) 2021 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据